Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian indices remain volatile
Thu, 6 Feb Closing

Indian equity markets had a rather volatile trading session today. While the indices began the day's proceedings on a positive note, selling activity intensified across index heavyweights in the subsequent hours and pushed the indices into the red. Buying resumed at lower levels in the afternoon session and led the indices to close the session above the dotted line. While the BSE-Sensex today closed higher by 50 points, the NSE-Nifty closed higher by 14 points. Both the BSE Mid Cap and the BSE Small Cap closed flat. Gains were largely seen in FMCG, metals and auto stocks.

As regards global markets, Asian indices closed mixed today while European indices have opened in the green. The rupee was trading at Rs 62.48 to the dollar at the time of writing.

Pharma stocks closed mixed today. While Sun Pharma and Cadila Healthcare found favour, Ranbaxy and Cipla closed into the red. Ranbaxy announced results for the fourth quarter and year ended December 2013. Consolidated global sales for the quarter were up 7% YoY. While branded formulations and the over-the-counter (OTC) segment accounted for 52% of total sales, the rest was made up of generics and API. The US, where the company is facing innumerable problems with the USFDA, accounted for 32% of total sales during the quarter. As per the management, the Toansa facility was issued a Form 483 containing certain observations in January 2014. This was subsequently included under certain provisions of the Consent Decree (CD) by USFDA. Because of this, Ranbaxy had suspended shipments of API to the USA market from this facility. The impact of this development was pegged at Rs 2.6 bn on account of stock write-offs and other related costs. As a result, the company reported a net loss before taxes to the tune of Rs 0.6 bn.

Bajaj Corp announced results for the third quarter and nine months ended December 2013. Net sales of the company grew by 6.7% YoY, while total expenditure rose at a higher rate of 10% leading to contraction in operating margins. Net profits plunged by 31% YoY. The same was largely due to the extraordinary expense of Rs 120 m related to brand amortization. Excluding the same, growth in net profits largely remained flat. The Board declared an interim dividend of Rs 6.5 per share, implying a dividend yield of 3%. The stock closed lower by 4% today.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian indices remain volatile". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.